Terms: = Liver cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
99 results:
1. Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
2. Serum alpha-fetoprotein response as a preoperative prognostic indicator in unresectable hepatocellular carcinoma with salvage hepatectomy following conversion therapy: a multicenter retrospective study.
Lin KY; Zhang JX; Lin ZW; Chen QJ; Luo LP; Chen JH; Wang K; Tai S; Zhang ZB; Wang SF; Li JD; Wang K; Zheng L; Zheng SM; Wu MM; Lin KC; Yang T; Zeng YY
Front Immunol; 2024; 15():1308543. PubMed ID: 38433845
[TBL] [Abstract] [Full Text] [Related]
3. Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving pd-1 blockade therapy.
Shen L; Tan H; Nie J; Jiang Y; Nuerhashi G; Qi H; Cao F; Wen C; Chen S; Zhang T; Zheng W; Liu P; Liu Y; Huang T; Li D; Zhang X; Fan W
Cancer Immunol Immunother; 2024 Mar; 73(4):68. PubMed ID: 38430269
[TBL] [Abstract] [Full Text] [Related]
4. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M; Barreira-Díaz A; Salcedo MT; Callejo-Pérez A; Muñoz-Couselo E; Iranzo P; Ortiz-Velez C; Cedrés S; Díaz-Mejía N; Ruiz-Cobo JC; Morales R; Aguilar-Company J; Zamora E; Oliveira M; Sanz-Martínez MT; Viladomiu L; Martínez-Gallo M; Felip E; Buti M
Aliment Pharmacol Ther; 2024 Apr; 59(7):865-876. PubMed ID: 38327102
[TBL] [Abstract] [Full Text] [Related]
5. Pan-cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours.
Chen Y; Gao Z; Mohd-Ibrahim I; Yang H; Wu L; Fu Y; Deng Y
Clin Transl Med; 2024 Feb; 14(2):e1543. PubMed ID: 38303608
[TBL] [Abstract] [Full Text] [Related]
6. Bioinformatic Analysis and Computer-Aided Study to Investigate the Potential Application of a Bioflavonoid Compound Bilobetin in liver cancer Treatment.
Zhang C; Sui Y; Liu S; Yang M
Front Biosci (Landmark Ed); 2023 Dec; 28(12):360. PubMed ID: 38179744
[TBL] [Abstract] [Full Text] [Related]
7. Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.
Peng K; Li Y; Su H; Lan C; Huang Z; Wei Y; Liao X; Peng M; Peng T; Zhu G
Front Immunol; 2023; 14():1325445. PubMed ID: 38173715
[TBL] [Abstract] [Full Text] [Related]
8. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
[TBL] [Abstract] [Full Text] [Related]
9. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
10. Combined hepatocellular cholangiocarcinoma in hepatectomy specimens: A clinicopathologic analysis.
Patil N; Sahai P; Rastogi A; Sharma N; Shasthry SM; Mukund A; Laroia ST; Kumar G; Pamecha V; Sarin SK
Indian J Pathol Microbiol; 2023; 66(4):744-750. PubMed ID: 38084526
[TBL] [Abstract] [Full Text] [Related]
11. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.
Abaza T; El-Aziz MKA; Daniel KA; Karousi P; Papatsirou M; Fahmy SA; Hamdy NM; Kontos CK; Youness RA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003674
[TBL] [Abstract] [Full Text] [Related]
12. CHSY1 promotes CD8
Sun G; Zhao S; Fan Z; Wang Y; Liu H; Cao H; Sun G; Huang T; Cai H; Pan H; Rong D; Gao Y; Tang W
J Exp Clin Cancer Res; 2023 Sep; 42(1):248. PubMed ID: 37749638
[TBL] [Abstract] [Full Text] [Related]
13. Significant response to transarterial chemoembolization combined with pd-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review.
Zhang H; Han C; Zheng X; Zhao W; Liu Y; Ye X
J Cancer Res Ther; 2023 Aug; 19(4):1055-1060. PubMed ID: 37675736
[TBL] [Abstract] [Full Text] [Related]
14. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma.
Zhang Z; Zhu XQ; Yang F; Lai NN; Zhu L; Cole K; Hu BY; Li TE; Zhu Y; Zhang LM; Wang S; Zheng Y; Mao H; Zhao Y; Bruns C; Vago R; Tu B; Wong JWH; Fu DL; Qin LX; Dong QZ
Med; 2023 Oct; 4(10):728-743.e7. PubMed ID: 37633269
[TBL] [Abstract] [Full Text] [Related]
15. Linear Peptide-Based PET Tracers for Imaging PD-L1 in Tumors.
Zhang L; Zhang S; Wu J; Wang Y; Wu Y; Sun X; Wang X; Shen J; Xie L; Zhang Y; Zhang H; Hu K; Wang F; Wang R; Zhang MR
Mol Pharm; 2023 Aug; 20(8):4256-4267. PubMed ID: 37368947
[TBL] [Abstract] [Full Text] [Related]
16. MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil.
Ji S; Xu M; Cai C; He X
Biochem Biophys Res Commun; 2023 Aug; 670():1-11. PubMed ID: 37271034
[TBL] [Abstract] [Full Text] [Related]
17. Hepatocellular carcinoma (HCC) immunotherapy by anti-pd-1 monoclonal antibodies: A rapidly evolving strategy.
Nikoo M; Hassan ZF; Mardasi M; Rostamnezhad E; Roozbahani F; Rahimi S; Mohammadi J
Pathol Res Pract; 2023 Jul; 247():154473. PubMed ID: 37207558
[TBL] [Abstract] [Full Text] [Related]
18. Immunotherapy for recurrent hepatocellular carcinoma.
Bhatt A; Wu J
World J Gastroenterol; 2023 Apr; 29(15):2261-2271. PubMed ID: 37124885
[TBL] [Abstract] [Full Text] [Related]
19. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract] [Full Text] [Related]
20. HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma.
Chen G; Zhang C; Li D; Luo D; Liao H; Huang P; Wang N; Feng Y
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830729
[TBL] [Abstract] [Full Text] [Related]
[Next]
